On June 1, Microsoft Corp. together with Merck & Co. Inc has signed an agreement to acquire certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatics LLC.

The deals allows Microsoft to incorporate genetic, genomic, metabolomic and proteomics data management software into the Microsoft Amalga Life Sciences platform which was introduced in April 2009, for enhanced translational research capabilities.

Microsoft Amalga Life Sciences platform is a new software platform intended to transform health and life sciences research data into the critical knowledge needed for the discovery of new treatments. The firm’s platform incorporating Rosetta Biosoftware technologies is schedule to be available in early 2010.

“The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data, helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine,” said Peter Neupert, corporate vice president, Health Solutions Group, Microsoft.

Microsoft will also create a strategic bond with Merck to improve the Amalga Life Sciences platform to meet rising pharmaceutical research needs.

“This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology, said Rupert Vessey, vice president, Merck Research Laboratories.

The conformity is expected to be sealed at the end of this month.